Charles M. Quick

High Impact

Professor

University of Arkansas for Medical Sciences

faculty

Pathology, College of Medicine

35 h-index 197 pubs 3,861 cited

Research Areas

Cancer Genomics and Diagnostics Cancer-related molecular mechanisms research Immune Response and Inflammation Gynecologic Cancer Research Medical Imaging Techniques and Applications Genomics and Phylogenetic Studies Diet and metabolism studies

Links

Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Charles M. Quick is a Professor in the Department of Pathology at the University of Arkansas for Medical Sciences (UAMS) College of Medicine. His research focuses on the integrated mutational landscape analysis of various gynecologic cancers, including uterine leiomyosarcomas and poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. He has also investigated the expansion of human papillomavirus-specific T cells in response to therapeutic vaccines, as well as the recurrent gynandroblastoma of the ovary associated with DICER1 mutations.

Dr. Quick's work extends to exploring the co-existence of diabetes and endometriosis and their potential impact on endometriosis progression. He has also contributed to research on the longitudinal monitoring of tumor response to immune checkpoint inhibitors using noninvasive diffuse reflectance spectroscopy and has examined the malignant potential of ovarian steroid cell tumors. His scholarship metrics include an h-index of 35, 197 total publications, and 3,861 total citations. He is recognized as a highly cited researcher and leads an active research group at UAMS, collaborating with colleagues such as Yong‐Chen Lu, Rosalia C.M. Simmen, Narasimhan Rajaram, and Sumit Shah.

Metrics

h-index: 35
Publications: 197
Citations: 3,861

Selected Publications

Isolation of mitochondrial mutation-specific T cell receptors (2025) DOI
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025) DOI
Interpretation of p16 and p53 in the Classification of Squamous Cell Carcinoma of the Vulva—An Interobserver Agreement Study (2024) DOI
Human quad liver-on-chip system as a tool toward bridging the gap between animals and humans regarding toxicology and pharmacology of a cannabidiol-rich cannabis extract (2024) DOI
Inter-strain variability in responses to a single administration of the cannabidiol-rich cannabis extract in mice (2024) DOI
Investigating the relationship between hypoxia, hypoxia-inducible factor 1, and the optical redox ratio in response to radiation therapy (2024) DOI
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix (2024) DOI
The Malignant Potential of Ovarian Steroid Cell Tumors Revisited (2024) DOI
Endometriosis and Endometriosis-Associated Tumors (2024) DOI
Gynecologic and Obstetric Pathology (2024) DOI
BHLHE40 drives protective polyfunctional CD4 T cell differentiation in the female reproductive tract against Chlamydia (2024) DOI
Coexpression of p53 and p16 in Vulvar Squamous Neoplasia (2023) DOI
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023) DOI
Uterine alveolar soft part sarcoma – an unexpected case (2023) DOI
Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023) DOI